Read by QxMD icon Read

American Journal of Clinical Oncology

Bin Gui, Ashley A Weiner, John Nosher, Shou-En Lu, Gretchen M Foltz, Omar Hasan, Seung K Kim, Vyacheslav Gendel, Naganathan B Mani, Darren R Carpizo, Nael E Saad, Timothy J Kennedy, Darryl A Zuckerman, Jeffrey R Olsen, Parag J Parikh, Salma K Jabbour
OBJECTIVE: As the utility of Child-Pugh (C-P) class is limited by the subjectivity of ascites and encephalopathy, we evaluated a previously established objective method, the albumin-bilirubin (ALBI) grade, as a prognosticator for yttrium-90 radioembolization (RE) treatment for patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A total of 117 patients who received RE for HCC from 2 academic centers were reviewed and stratified by ALBI grade, C-P class, and Barcelona Clinic Liver Cancer stage...
April 17, 2017: American Journal of Clinical Oncology
Brian J Gebhardt, James P Ohr, Robert L Ferris, Umamaheswar Duvvuri, Seungwon Kim, Jonas T Johnson, Dwight E Heron, David A Clump
OBJECTIVES: Adjuvant radiation therapy (RT) is indicated for patients with salivary gland malignancies with risk factors for recurrence following resection. We analyzed patients treated with adjuvant RT with or without concurrent chemotherapy to determine the impact of prognostic and treatment factors. MATERIALS AND METHODS: Retrospective analysis was performed of 128 patients treated with surgical resection followed by intensity-modulated radiotherapy. In total, 31 (24...
April 7, 2017: American Journal of Clinical Oncology
Christina A Kim, Quincy S C Chu, Konrad Fassbender, Sunita Ghosh, Jennifer L Spratlin
OBJECTIVES: Patients with advanced pancreatic cancer (APC) have a poor prognosis and experience a large burden of disease-related symptoms. Despite advancements in the treatment of APC, survival is dismal and controlling disease-related symptoms and maintaining quality of life is paramount. We hypothesize that an improvement in disease-related symptoms, and therefore, a clinical benefit, while on chemotherapy is a predictive marker in APC. MATERIALS AND METHODS: Patients 18 and older with APC diagnosed between January 1, 2005 and December 31, 2010 and treated at the Cross Cancer Institute were identified using the provincial cancer registry...
March 31, 2017: American Journal of Clinical Oncology
Sarah E Pesek, Heather M King, Susan Koelliker, Christina Raker, David Edmonson, Don S Dizon, Jennifer Gass
OBJECTIVES: Axillary ultrasound with fine needle aspiration (AXUSFNA) in early-stage breast cancer has required reappraisal. ACOSOG Z-0011 and after mapping of the axilla: radiotherapy or surgery have shown that women with limited nodal disease at sentinel lymph node biopsy got no survival advantage with completion axillary node dissection. We hypothesize that AXUSFNA may be sufficiently accurate for staging for some patients and sentinel lymph node biopsy need not be performed. We define the false negative rate (FNR) of AXUSFNA in different subsets of patients...
March 23, 2017: American Journal of Clinical Oncology
Lena Sagi-Dain, Ofer Lavie, Ron Auslander, Shlomi Sagi
OBJECTIVE: To estimate the diagnostic performance and reference values of serum cancer antigen (Ca)15-3 levels in the triage of adnexal masses. MATERIALS AND METHODS: This retrospective cohort study was carried out in 481 patients referred to the Gynecology Department at Carmel Medical Center due to adnexal mass between years 2005 and 2012. All patients underwent surgery with histopathologically confirmed diagnosis and routine preoperative measurements of serum Ca125 and Ca15-3...
March 23, 2017: American Journal of Clinical Oncology
Dana B Cardin, Ramya Thota, Laura W Goff, Jordan D Berlin, Clyde M Jones, Gregory D Ayers, Jennifer G Whisenant, Emily Chan
OBJECTIVES: Heat shock protein 90 regulates multiple signaling proteins involved in key pathways of pancreatic cancer pathogenesis. Ganetespib binds to heat shock protein 90 and interferes with its binding to client proteins thus leading to inactivation and degradation of the signaling proteins that promote cancer progression. This phase II study was designed to evaluate the efficacy of ganetespib in patients with refractory metastatic pancreatic cancer (rMPC). METHODS: Patients with rMPC received 175 mg/m ganetespib intravenously once weekly for 3 weeks in 4-week cycles...
March 15, 2017: American Journal of Clinical Oncology
Daniel J Becker, Benjamin P Levy, Heather T Gold, Scott E Sherman, Danil V Makarov, David Schreiber, Juan P Wisnivesky, Harvey I Pass
OBJECTIVES: Despite previous retrospective reports that the number of lymph nodes resected at curative intent surgery for lung cancer correlates with overall survival (OS), no consensus exists regarding the minimal nor optimal number of lymph nodes to resect at curative lung cancer surgery. METHODS: We studied subjects in the Surveillance Epidemiology and End Results Database (SEER) diagnosed with non-small cell lung cancer between 2000 and 2011 who underwent either lobectomy or pneumonectomy and had pathologic negative nodal evaluation...
March 15, 2017: American Journal of Clinical Oncology
Amar U Kishan, Gillian Duchesne, Pin-Chieh Wang, Jean-Claude M Rwigema, Arun U Kishan, Christopher Saigal, Matthew Rettig, Michael L Steinberg, Christopher R King
OBJECTIVE: To query specialty-specific differences regarding postoperative radiotherapy (RT) for high-risk prostate cancer. MATERIALS AND METHODS: Electronic mail survey of radiation oncologists (ROs) and urologists. We sought to maximize absolute response number to capture contemporary practice ethos. The outcome of interest was association between response and specialty. Training level/expertise, practice setting, percentage of consultation caseload consisting of high-risk prostate cancer, and nationality were set as effect modifiers for multivariate logistic regression...
March 15, 2017: American Journal of Clinical Oncology
Emory McTyre, John T Lucas, Corbin Helis, Michael Farris, Michael Soike, Ryan Mott, Adrian W Laxton, Stephen B Tatter, Glenn J Lesser, Roy E Strowd, Hui-Wen Lo, Waldemar Debinski, Michael D Chan
OBJECTIVES: Postoperative management of anaplastic glioma remains without a clear standard of care-in this study we report outcomes for patients treated with radiotherapy (RT) with and without temozolomide (TMZ). MATERIALS AND METHODS: We identified 71 consecutive patients with World Health Organization grade III glioma treated with either RT alone or with concurrent TMZ (RT+TMZ), between 2000 and 2013. Tumor histology was anaplastic astrocytoma in 42 patients, anaplastic oligodendroglioma in 25 patients, and anaplastic oligoastrocytoma in 4 patients...
March 15, 2017: American Journal of Clinical Oncology
Yong Liu, Guoqi Zhao, Yi Xu, Tiening Zhang, Zhixiao Chen, Ge Yan, Wenzhi Tu, Ye Hu, Ying Chen, Xia He, Xiaodong Li, Hui Chen, Shengyu Yao, Zhekai Hu, Xuming Chen, Tingfeng Chen
OBJECTIVES: The Intergroup 0116 study has demonstrated a significant survival benefit for completely resected (R0) gastric cancer patients treated with a fluorouracil/leucovorin chemoradiotherapy regimen. However, this regimen is also toxic and less effective in terms of distant disease control. Therefore, a more efficacious and safer regimen is urgently needed. METHODS: Patients with R0 resected gastric carcinoma received up to two 21-day cycles of postoperative adjuvant preradiation and postradiation DCF chemotherapy (docetaxel 37...
March 3, 2017: American Journal of Clinical Oncology
Elizabeth M Gleeson, Rebecca Feldman, Beth L Mapow, Lynn T Mackovick, Kristine M Ward, William F Morano, Rene R Rubin, Wilbur B Bowne
OBJECTIVES: Pseudomyxoma peritonei (PMP) is a rare malignancy originating from the appendix, characterized by disseminated mucinous tumor implants on peritoneal surfaces. We examined the role of multiplatform molecular profiling to study biomarker-guided treatment strategies for this rare malignancy. METHODS: A total of 54 patients with appendix-derived PMP were included in the study. Tests included one or more of the following: gene sequencing (Sanger or next generation sequencing), protein expression (immunohistochemistry), and gene amplification (C/fluorescent in situ hybridization)...
March 3, 2017: American Journal of Clinical Oncology
Chi Zhang, Vivek Verma, Elizabeth R Lyden, David P Horowitz, Brad E Zacharia, Chi Lin, Eileen P Connolly
OBJECTIVE: Assess patterns of care in the management of craniopharyngioma, especially with respect to the use of radiation therapy (RT) alone (which has been understudied to date) as compared with gross total resection (GTR) and subtotal resection (STR) with adjuvant RT. MATERIALS AND METHODS: The epidemiology, treatment modalities, and outcomes of patients with craniopharyngioma were studied using the Surveillance Epidemiology and End Results (SEER) database from 2004 to 2012...
March 3, 2017: American Journal of Clinical Oncology
Shing Fung Lee, Ting Ying Ng, Frank Chi Sing Wong, Stewart Yuk Tung
OBJECTIVES: The role of radiotherapy (RT) in improving survival of patients with diffuse large B-cell lymphoma (DLBCL) of the Waldeyer ring (WR) remains controversial. Therefore, this retrospective cohort study aimed to determine the role of RT in the treatment of DLBCL of the WR as well as the effects of associated covariates. MATERIALS AND METHODS: Patients (n=35) with stage I to II DLBCL of the WR who underwent treatment at our center between 1994 and 2010 were retrospectively investigated...
March 3, 2017: American Journal of Clinical Oncology
William E Jones, W Waren Suh, May Abdel-Wahab, Ross A Abrams, Nilofer Azad, Prajnan Das, Jadranka Dragovic, Karyn A Goodman, Salma K Jabbour, Andre A Konski, Albert C Koong, Rachit Kumar, Percy Lee, Timothy M Pawlik, William Small, Joseph M Herman
Management of resectable pancreatic adenocarcinoma continues to present a challenge due to a paucity of high-quality randomized studies. Administration of adjuvant chemotherapy is widely accepted due to the high risk of systemic spread associated with pancreatic adenocarcinoma, but the role of radiation therapy is less clear. This paper reviews literature associated with resectable pancreatic cancer to include prognostic factors to aid in the selection of patients appropriate for adjuvant therapies. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel...
April 2017: American Journal of Clinical Oncology
Lynn E Spitler, Huynh Cao, Timo Piironen, Theresa L Whiteside, Robert W Weber, Scott Cruickshank
OBJECTIVES: We investigated the development of binding and neutralizing antibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients receiving prolonged therapy with GM-CSF as adjuvant therapy of melanoma and the impact of these antibodies on biological effects. METHODS: Fifty-three patients with high-risk melanoma that had been surgically excised were treated with GM-CSF, 125 ╬╝g/m daily for 14 days every 28 days for 1 year after surgical resection of disease...
April 2017: American Journal of Clinical Oncology
Gwang Hyeon Choi, Seungbong Han, Ju Hyun Shim, Min-Hee Ryu, Baek-Yeol Ryoo, Yoon-Koo Kang, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
BACKGROUND: The purpose of this study was to build prognostic models capable of estimating the outcomes of individual sorafenib-treated advanced stage hepatocellular carcinoma (HCC) patients based on specific patient and tumor factors. METHODS: A parametric model for time-to-event data was used to construct scoring systems based on the intent-to-treat data set from 480 sorafenib-treated patients with advanced stage HCC: 356 for derivation and 124 for validation...
April 2017: American Journal of Clinical Oncology
Raju R Raval, Deborah Frassica, Katherine Thornton, Christian Meyer, David S Ettinger, Frank Frassica, Kristin Weber, Stephanie A Terezakis
OBJECTIVES: High-grade soft-tissue sarcoma (STS) has a poor prognosis. The goal of this study was to review treatment outcomes of patients with high-grade STS treated with interdigitated neoadjuvant chemotherapy (CT) and radiation at our institution. MATERIALS AND METHODS: Patients with high-grade STS (1997 to 2010) were planned for treatment with 3 cycles of neoadjuvant CT, interdigitated preoperative radiation therapy (44 Gy administered in split courses with a potential 16 Gy postoperative boost), and 3 cycles of postoperative CT...
April 2017: American Journal of Clinical Oncology
Nadeem Pervez, Alex Boychak, Claudia S Drodge, Don Yee, Duc Le, Albert Murtha, Matthew Parliament, John Amanie, Alina Mihai, Colin Field, Marc Mackenzie, Sunita Ghosh, Gino Fallone, Robert Pearcey
OBJECTIVE: To assess late toxicity and outcomes in high-risk prostate cancer patients treated with hypofractionated radiation treatment with androgen suppression therapy. METHODS: Sixty high-risk prostate cancer patients were enrolled. IMRT prescription was 68 Gy/25 fractions (2.7 Gy/fraction) to the prostate and proximal seminal vesicles (SV). The pelvic lymph nodes (PLN) and distal SV concurrently received 45 Gy/25 fractions (1.8 Gy/fraction). The patients were treated with helical TomoTherapy-based IMRT and underwent daily megavoltage CT image-guided verification before each treatment...
April 2017: American Journal of Clinical Oncology
Terence T Sio, Jackson J Liang, Kenneth Chang, Ritujith Jayakrishnan, Paul J Novotny, Abhiram Prasad, Robert C Miller
OBJECTIVES: To retrospectively evaluate outcomes among cancer survivors previously treated with thoracic radiotherapy (RT) who later underwent percutaneous coronary intervention (PCI). METHODS: From 1998 to 2012, 76 patients first received curative RT (>30 Gy, except for Hodgkin lymphoma patients) involving the heart and lungs followed by PCI. Heart and lung-specific dosimetric parameters were correlated with overall survival (OS) and cardiac-specific survival by Cox variate methods...
April 2017: American Journal of Clinical Oncology
Mary J Ninan, Yang Liu, Yong-Fang Kuo, James S Goodwin
OBJECTIVES: To estimate the rates of hospitalizations in patients within 12 months after the first rituximab administration. METHODS: Patients who received rituximab between 2001 and 2008 for either benign or malignant conditions were identified from Texas Medicare files. The hospitalization rates for these patients with any diagnoses that might represent toxicity were then compared in the 12 months before and after the first infusion of rituximab. Dose-response analyses were performed on the basis of the number of doses received in the 8 weeks after initiating rituximab and also using the cumulative number of doses as a time-dependent covariate...
April 2017: American Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"